United States · Bill · HR
H.R. 6897 (118th)
Synthetic Biology and Active Pharmaceutical Ingredients Act
Introduced
22 December 2023
Last action
—
Status
Referred to the House Committee on Armed Services.
Sponsors
—
Subjects
Discovery layer
Source updated
6 June 2025
Summary
Synthetic Biology and Active Pharmaceutical Ingredients Act This bill requires the Department of Defense (DOD) to establish a pilot program to support domestic manufacturing of critical pharmaceutical ingredients and their components through certain novel technology. Specifically, DOD must establish a three-year program that uses technology involving synthetic biology to support domestic manufacturing of pharmaceutical ingredients and related incorporated materials that (1) are not available in a sufficient quantity or quality domestically, and (2) are strategically important to the United States.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 22 December 2023
Introduced in House (PDF)
Introduced in House · EN · 22 December 2023
Introduced in House
summary · EN · 22 December 2023
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/118th-congress/house-bill/6897
- Open data entity: https://api.congress.gov/v3/bill/118/hr/6897